Literature DB >> 28596140

Formation, characterization and pH dependence of rifampicin: heptakis(2,6-di-O-methyl)-β-cyclodextrin complexes.

Lorenzo Angiolini1, Marco Agnes2, Boiko Cohen1, Konstantina Yannakopoulou3, Abderrazzak Douhal4.   

Abstract

Rifampicin (Rif) is a broad spectrum antibiotic used as a first line agent in the treatment of mycobacterial infections. However, its low solubility and reduced stability in water limit its bioavailability, thus requiring the use of complex formulations. Here, we present a systematic study of Rif in complex with a methylated cyclodextrin, heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB), in phosphate buffer using a combination of nuclear magnetic resonance (NMR) and steady-state UV-vis spectroscopic methods. An increase in the stability and solubility of Rif in complex with DIMEB was observed in buffered solutions (phosphate, PBS). At neutral pH the presence of three distinguishable binding sites was revealed, demonstrating that DIMEB forms predominantly a stable 1:1 (K∼3000M-1) complex at the piperazine site of Rif, while at acidic pH the binding constant decreases significantly (K∼400M-1) due to protonation of the piperazine, thus inducing a release of Rif. The reported results provide new and relevant information for the stability and solubility of Rif in aqueous solution when forming a complex with DIMEB. Furthermore they contribute to clarify Rif interactions with cyclodextrin carriers, thus providing the basis for the development of new methylated cyclodextrin that can efficiently encapsulate and deliver Rif and derivatives of its family.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cyclodextrins; Drug delivery system; Heptakis(2,6-di-O-methyl)-β-cyclodextrin (PubChem CID: 122130377); NMR spectroscopy; Rifampicin; Rifampicin (PubChem CID: 6913622); UV–vis spectroscopy; pH-controlled release

Mesh:

Substances:

Year:  2017        PMID: 28596140     DOI: 10.1016/j.ijpharm.2017.06.015

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Dual Drug Loaded pH-sensitive Micelles for Efficient Bacterial Infection Treatment.

Authors:  Yingxian Chen; Qian Zhao; Junhua Han; Xinmiao Lan; Jing Che; Meiwan Chen; Xing-Jie Liang; Xiaowei Ma
Journal:  Pharm Res       Date:  2022-02-14       Impact factor: 4.200

2.  Repurposing Bedaquiline for Effective Non-Small Cell Lung Cancer (NSCLC) Therapy as Inhalable Cyclodextrin-Based Molecular Inclusion Complexes.

Authors:  Vineela Parvathaneni; Rasha S Elbatanony; Mimansa Goyal; Tejashri Chavan; Nathan Vega; Srikanth Kolluru; Aaron Muth; Vivek Gupta; Nitesh K Kunda
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

3.  Assessment of persistent antimicrobial and anti-biofilm activity of p-HEMA hydrogel loaded with rifampicin and cefixime.

Authors:  Ola Tarawneh; Hadeel Abu Mahfouz; Lama Hamadneh; Ahmad A Deeb; Iyad Al-Sheikh; Wasan Alwahsh; Abdulqader Fadhil Abed
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

4.  Multifunctional antibiotic- and zinc-containing mesoporous bioactive glass scaffolds to fight bone infection.

Authors:  C Heras; J Jiménez-Holguín; A L Doadrio; M Vallet-Regí; S Sánchez-Salcedo; A J Salinas
Journal:  Acta Biomater       Date:  2020-07-24       Impact factor: 10.633

5.  Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae.

Authors:  Sundeep Chaitanya Vedithi; Sony Malhotra; Madhusmita Das; Sheela Daniel; Nanda Kishore; Anuja George; Shantha Arumugam; Lakshmi Rajan; Mannam Ebenezer; David B Ascher; Eddy Arnold; Tom L Blundell
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.